BOOKMARK
  • Korean|
  • Chinese|
  • Japanese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
NEWS > Business > article

Celltrion aims to become world's top three biotech firms in 2020

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : March 23, 2018, 15:46 | Updated : March 23, 2018, 15:46
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]


SEOUL -- Buoyed by the growing popularity of biosimilar drugs, the head of South Korea's leading biopharmaceutical venture group Celltrion unveiled an ambitious project Friday to nurture his company as one of the world's three major biotech firms through active expansion.

"We will be reborn as a comprehensive pharmaceutical company," Chairman Seo Jung-jin told shareholders in a telephone speech from Austria, adding Cenlltrion aims to become one of the world's three largest biotech companies in 2020.

Celltrion has disclosed a plan to build a third plant overseas at a location selected in the first half of the year. Seo said his group could build a wholly-owned factory in an unidentified Asian country. "We will put a priority on the country where Celltrion can secure a 100 percent stake to prevent technology spills."

In December last year, Celltrion forged a joint venture deal with Tasly, a Chinese pharmaceutical company. "For our entry into China, we plan to complete the establishment of a Chinese subsidiary in the first half of this year," Seo said, adding his company may seek the acquisition of an Indian company to strengthen the synthetic drug business.

Celltrion's stock, coveted by foreign and domestic investors, has surpassed Hyundai Motor's in terms of market value.

In 2017, Celltrion's net profit rose to 403 billion won from 221 billion won a year ago, helped by brisk sales of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease. Truxima, used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis, is also popular in Europe. Herzuma is used to treat breast cancer.

 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .S. Korean anti-cancer biosimilar Truxima wins approval in Australia.
    S. Korean anti-cancer biosimilar Truxima wins approval in Au…
  • .Biosimilar drug company Celltrion shows stellar performance last year .
    Biosimilar drug company Celltrion shows stellar performance …
  • .S. Korea approves sales of domestic anti-cancer biosimilar.
    S. Korea approves sales of domestic anti-cancer biosimilar
  • .SK tops per-capita productivity .
    SK tops per-capita productivity

Real Time Photo News

  • .Super Junior becomes first K-pop group to enter Billboards Latin Songs Chart.

    Super Junior becomes first K-pop group to enter Billboard's Latin Songs Chart

  • .New ​Avengers sets new box-office record on opening day in S. Korea.

    New ​'Avengers' sets new box-office record on opening day in S. Korea

  • .Suzy makes warm-hearted donation for single mothers.

    Suzy makes warm-hearted donation for single mothers

  • .​BTS to premiere new song at Billboard Music Awards in May.

    ​BTS to premiere new song at Billboard Music Awards in May

  • .Rapper Locco and MAMAMOOs Hwasa dominate charts with Dont give it to me.

    Rapper Locco and MAMAMOO's Hwasa dominate charts with 'Don't give it to me'

Latest News

more+

  • ​BTS promotes LG's latest flagship G7 in YouTube video
  • LG acquires Austria's premium headlamp maker ZKW
  • ​Hyundai Motor's net profit halves due to slow sales in US and China
  • Koreans await historic summit on rapprochement in truce village
  • ​Leaders of two Koreas to plant commemorative tree in truce village
Aju Business Daily
Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, SeoulContact us : swatchsjp@ajunews.com
Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.
Mobile view